Redefining cancer treatment with next-generation bispecific & multispecific antibodies.
Disruptive innovation in immunotherapy of Cancer, based on proprietary BiXAb® bispecific and multispecific antibody technologies.
Introduction
Breakthrough Antibody-Based Therapies in Immuno-Oncology.
BIOMUNEX Pharmaceuticals is a biopharmaceutical specializing in the discovery and development of innovative therapeutic approaches based on solid data and biological and clinical evidence to address unmet medical needs in oncology.
At the core of our innovation is BiXAb®, proprietary next-generation platform technologies designed to generate innovative bi- and multi-specific antibodies.
A large panel of Bispecific antibodies: BiXAb® enables the simple, rapid, and cost-efficient generation of bispecific antibodies from any pair of monoclonal antibodies as building blocks. These platform technologies have already been validated through strategic collaborations and licensing agreements with leading industry players, including Ipsen, Sanofi, and Onward Therapeutics.
Our proprietary flagship program, the BiXAb-MAIT engagers, uses the BiXAb platform technologies, with bispecific antibodies that identify, mobilize and bridge MAIT cells (Mucosal-Associated Invariant T cells), present in all body and particularly in mucosal and barrier tissues, to specifically engage and kill cancer cells in solid tumors. MAIT engagers are expected to overcome some of the limitations of current CD3+ T cell engagers (TCEs), including activation of regulatory T cells (Tregs) and cytokine release syndrome, serious side effects that are difficult to manage for cancer patients.
Science
Our key BiXAb antibody Platform technologies.
BiXAb® Technologies
Best-in-class, proprietary platform technologies enabling the discovery and development of next-generation bispecific & multi-specific antibodies for cancer treatment.
MAIT Engagers
Biomunex’s unique therapeutic approach designed to engage MAIT cells to target and kill cancer cells with high specificity.
Other Bispecific Antibodies (BsAb)
A broad and expanding pipeline of BiXAb® bispecific and multi-specific antibodies for disruptive innovation.
Our Science at a Glance
We are committed to transforming cancer treatment by developing next-generation immunotherapies that go beyond traditional monoclonal antibodies.
BiXAb® Platform
Fast, robust, versatile bi- and multi-specific antibodies
MAIT Engagers
A first-in-class approach to mobilize a unique T-cell subset
Pipeline
Innovative programs from discovery to clinical development, in collaboration with global leaders
About
Understand our technology in 3 questions to Biomunex’s management Team
Pierre-Emmanuel Gerard, Founder, President & CEO and Simon Plyte, CSO
Partnering
Trusted by Leading Partners
We collaborate with leading pharmaceutical companies and world-class research institutions to accelerate innovation and bring new therapies to patients.
Key figures
+10
Years of research in immuno-oncology
3
Licensed clinical programs
2
“Deal of The Year” awards nominations
610m
Dollars in potental milestones with Ipsen
Careers
Join Our Mission
We are building a passionate and talented team to shape the future of cancer immunotherapy.
